AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
